Thromboelastography is a technique for determining the effectiveness of blood coagulation. Nonetheless, its use in resuscitations in emergency rooms, intensive care units, and delivery rooms is increasing. The test is mostly used in surgery and anesthesia. TEG (thromboelastography) is a non-invasive technique for determining the clotting propensity of whole blood. The goal of this in vitro test is to detect and quantify dynamic changes in the viscoelastic characteristics of a blood sample that occur during clotting under mild shear stress. Since more industry players are releasing products, the global thromboelastography market is anticipated to grow throughout the course of the projected period. Over the forecast period, an increase in R&D activities is anticipated to fuel market expansion for thromboelastography worldwide.
The global market for Thromboelastography is anticipated to expand at a CAGR of 7.1% from 2022 to 2030.
Prominent Players in the Thromboelastography Industry:
1. Lepu Medical Technology (Beijing) Co., Ltd.
Lepu Medical Technology (Beijing) Co., Ltd. was founded in 1999 and headquartered in Beijing, China. It operates in more than 80 countries.
2. Render Biotech Co.
Render Biotech Co. was founded in 2016 and headquartered in Guangming, Shenzhen. It operates in Asia and distributors around the globe. On MEDICA 2022 in November 2022, Render announced the first highest throughput completely automated Thromboelastography IHTEG series by Render independent research and development.
3. Haemonetics Corporation
Haemonetics Corporation is a global provider of blood and plasma supplies and services. It was founded in 1971 and headquartered in Massachusetts, USA. It operates in 50 countries. For the length of the COVID-19 public health emergency, Haemonetics Corporation, a worldwide medical technology company focused on providing creative medical solutions to enhance patient outcomes, affirms its support for updated FDA recommendations on the use of viscoelastic testing in January 2021. Haemonetics is moving fast to update the indications for the TEG® 5000 and TEG® 6s hemostasis analyzers, as well as any associated assays, in compliance with FDA recommendations by revising product labeling and usage instructions. Healthcare professionals will be able to start using TEG® devices throughout the pandemic to enhance patient care.